

## Synthesis of Chiral Prostanoid Intermediates from Phenol

By MELVYN GILL and RODNEY W. RICKARDS\*

*(Research School of Chemistry, Australian National University, Canberra, A.C.T. 2600, Australia)*

**Summary** The 2-substituted derivatives of (4*R*)-4-hydroxycyclopent-2-enone (**11**) and (**12**), important intermediates in prostaglandin synthesis, are prepared from

(4*S*)-3-chloro-4-(dimethyl-*t*-butylsilyloxy)cyclopent-2-enone (**4**) which is available in five steps from phenol.


---

We report an efficient general synthesis from phenol of chiral 2-substituted 4-hydroxycyclopent-2-enones, *e.g.* (12), which are important intermediates in prostanoïd synthesis<sup>1</sup> since their ethers undergo stereospecific conjugate addition reactions to yield 2,3-disubstituted 4-hydroxycyclopent-anones possessing the natural prostaglandin configuration. For example, (–)-PGE<sub>1</sub> (13) is produced from the (4*R*)-tetrahydropyranyl ether (11) either by reaction with the appropriate chiral *trans*-vinyl cuprate,<sup>2</sup> or by kinetic resolution of a racemic *cis*-divinyl cuprate<sup>3</sup> followed by correction of side chain stereochemistry.<sup>4</sup> The (4*R*)-4-hydroxycyclopent-2-enone (12) has been prepared by microbiological reduction of 2-(6-methoxycarbonylhexyl)-cyclopentane-1,3,4-trione,<sup>2</sup> synthesis from D-glyceraldehyde,<sup>3</sup> or resolution of its diastereoisomeric oximes.<sup>5</sup> Microbiological hydroxylation of 2-(6-carboxyhexyl)cyclopent-2-enone gave the (4*R*)-hydroxy acid corresponding to the ester (12) in only 34% enantiomeric excess.<sup>6</sup> The early incorporation of the potential 2-alkyl substituent in the existing routes to chiral intermediates of the type (12) impedes their use for the production of prostanoïds modified in the α-chain.

The present route makes a variety of 2-substituted (4*R*)-4-hydroxycyclopent-2-enones readily available from a common chiral precursor. This key synthon, (4*S*)-3-chloro-4-(dimethyl-*t*-butylsilyloxy)cyclopent-2-enone (4), is prepared from phenol in five steps, chirality being introduced at the second step. Easy replacement of the vinylic chlorine in (4) by functionalised alkyl chains leads, after stereospecific transposition of the oxygen functions, to the required prostanoïd intermediates. In conjunction with previous work,<sup>2–4</sup> this constitutes a new route to prostanoïds in which *both* side chains are attached to a chiral cyclopentenone by conjugate addition reactions. The route is illustrated here by the synthesis of the established precursors (11) and (12) of (–)-PGE<sub>1</sub> (13).



Ring contraction of phenol or 2,4,6-trichlorophenol with alkaline hypochlorite<sup>7</sup> yields the acid (1) in 50–60% yield as a racemate with the relative configuration shown.<sup>8</sup> Crystallisation of the diastereoisomeric brucine salts from methanol gave the desired (1*R*,4*R*)-enantiomer (1) as its (–)-brucine salt, m.p. 143–146 °C,  $[\alpha]_D^{25} - 120^\circ$  (*c* 0.247, CHCl<sub>3</sub>), optically pure in 74% yield after one recrystallisation. Acidification gave the free (1*R*,4*R*)-acid (1), m.p. 188–190 °C,  $[\alpha]_D^{25} - 207^\circ$  (*c* 0.100, EtOH),  $[\theta]_{219}^{25} - 75,500$  (*c* 5.18 × 10<sup>–3</sup>, EtOH). Oxidative decarboxylation with lead tetra-acetate<sup>9</sup> of the acid (1) afforded in 98% yield the (4*R*)-trichlorocyclopentenone (2),  $[\theta]_{333}^{25} + 8410$  (*c* 5.66 × 10<sup>–2</sup>, EtOH). Partial dechlorination with chromous chloride (H<sub>2</sub>O–acetone; 0 °C)† and protection of the hydroxy-function (Me<sub>3</sub>Bu<sup>t</sup>SiCl, hexamethylphosphoric triamide; 2 °C) in the resulting unstable (4*S*)-chlorocyclopentenone (3)‡ proceeded in 61% overall yield to give (4*S*)-3-chloro-4-(dimethyl-*t*-butylsilyloxy)cyclopent-2-enone (4) as a stable oil,  $[\theta]_{333}^{25} + 6700$  (*c* 9.14 × 10<sup>–2</sup>, hexane),  $\lambda_{\max}(\text{hexane})$  222 nm ( $\epsilon$  13,900),  $\nu_{\max}(\text{film})$  1730 cm<sup>–1</sup> (CO),  $\delta$  (CDCl<sub>3</sub>) 6.22 (1H, d, *J* 1 Hz, 2-H), 4.84 (1H, ddd, *J* 6, 2.4, and 1 Hz, 4-H), 2.87 (1H, dd, *J* 18.3 and 6 Hz, 5α-H), and 2.43 (1H, dd, *J* 18.3 and 2.4 Hz, 5β-H). Significantly, the (4*R*)-enantiomer of this synthon (4) possesses the hydroxy-con-

figuration corresponding to that of natural prostaglandins. Since it also is a useful prostanoid precursor,<sup>10</sup> the intrinsic loss of material normally involved in a resolution does not occur upon resolution of the racemic acid (1).



The synthon (4) underwent rapid conjugate addition–elimination with the Grignard reagent (5) in the presence of cuprous iodide (tetrahydrofuran; –10 °C; 10 min) to form the (4*S*)-cyclopentenone (6) in 89% yield,  $[\theta]_{336}^{25} + 8540$  (*c* 1.665 × 10<sup>–2</sup>, hexane),  $\nu_{\max}(\text{film})$  1720 cm<sup>–1</sup> (CO),  $\delta$  (CDCl<sub>3</sub>) 5.90 (1H, dt, *J* ca. 1 and 1 Hz, 2-H), 4.76 (1H, m, 4-H), and 3.60 (2H, t, *J* 6 Hz, CH<sub>2</sub>OSiMe<sub>2</sub>Bu<sup>t</sup>).

Stereospecific transposition of the ring oxygen functions in the (4*S*)-cyclopentenone (6) was initiated by reduction with lithium tri-*s*-butylborohydride (tetrahydrofuran; –78 °C) in 82% yield to the (1*R*,4*S*)-cyclopentenol (7),  $\nu_{\max}(\text{film})$  3600–3100 cm<sup>–1</sup> (OH),  $\delta$  (CDCl<sub>3</sub>) 5.54 (1H, m, 2-H), 4.52 (2H, m, 1-H and 4-H), and 2.68 (1H, dt, *J* 14 and 7 Hz, 5α-H). The stereohomogeneity of the product (7) was established from its <sup>13</sup>C n.m.r. spectrum, and the 1,4-*cis* relationship of its ring oxygen functions follows from analysis of the 5α-H resonance which is equally coupled to 1-H and 4-H.<sup>11</sup> Tetrahydropyranylation in 75% yield of



thp = tetrahydropyran-2-yl.

† We are indebted to Dr. R. M. Christie for preliminary work on this reaction.

‡ Identity established by t.l.c. comparison with the fully characterised racemate, and used without purification.

the newly formed hydroxy group of (7), followed by fluoride cleavage<sup>12</sup> of both silyl ethers (tetrahydrofuran, 0 °C) in the product (8) gave the (1*S*,4*R*)-cyclopentenol (9)§ as a 1:1 mixture of diastereoisomers in 93% yield,  $\nu_{\max}(\text{film})$  3700—2500  $\text{cm}^{-1}$  (OH),  $\delta(\text{CDCl}_3)$  5.63 (1H, m, 3-H), 4.85—4.25 (3H, m, 1-H, 4-H, and —OCHO—), and 2.71 and 2.63 (each 0.5H, dt,  $J$  14 and 7 Hz, 5 $\alpha$ -H in diastereoisomers). Treatment of (9) with Jones reagent (–20 °C; 3 h) completed the transposition of ring functionality and oxidised the side chain alcohol to the (4*R*)-keto-acid (10), which was methylated with diazomethane. The resulting (4*R*)-tetrahydropyranyl ether (11), obtained in 83% yield from the cyclopentenol (9),  $\nu_{\max}(\text{film})$  1735 ( $\text{CO}_2\text{Me}$ ) and 1710  $\text{cm}^{-1}$  (CO),  $\delta(\text{CDCl}_3)$  7.20 (1H, m, 3-H) and 3.66 (3H, s,  $\text{CO}_2\text{Me}$ ), exhibited a negative Cotton effect at long wavelength,  $[\theta]_{323}^{25} - 11,300$  ( $c$   $4.47 \times 10^{-2}$ , MeOH), thus confirming the reversal of configuration at C-4 relative to the (4*S*)-cyclopentenone (6).

Hydrolysis of the tetrahydropyranyl ether of (11) (HOAc,  $\text{H}_2\text{O}$ , tetrahydrofuran) removed the source of diastereoisomerism and gave (4*R*)-4-hydroxy-2-(6-methoxycarbonylhexyl)cyclopent-2-enone (12) in 88% yield, m.p. 57—59 °C (lit.,<sup>3</sup> m.p. 60—60.5 °C),  $\nu_{\max}(\text{KBr})$  3350 (OH), 1735 ( $\text{CO}_2\text{Me}$ ), and 1710  $\text{cm}^{-1}$  (CO),  $\delta(\text{CDCl}_3)$  7.12 (1H, dt,  $J$  3 and 1.5 Hz, 3-H), 4.94 (1H, m, 4-H), 3.66 (3H, s,  $\text{CO}_2\text{Me}$ ), 2.80 (1H, dd,  $J$  18.5 and 6 Hz, 5 $\beta$ -H), and 2.28 (1H, dd,  $J$  18.5 and 2 Hz, 5 $\alpha$ -H), u.v. and  $^{13}\text{C}$  n.m.r. data in agreement with published data.<sup>2,3</sup> Comparison of the c.d.,  $[\theta]_{320}^{25} - 9860$  ( $c$   $4.14 \times 10^{-2}$ , MeOH), of (12) with literature data ( $[\theta]_{321} - 9150$ ,<sup>3</sup> and  $-9900$ )<sup>2</sup> confirms the optical integrity of the synthesis.

We are indebted to Mr. A. J. Herlt for skilful technical assistance.

(Received, 24th October 1978; Com. 1143.)

§ I.U.P.A.C. Nomenclature requires a change of numbering in the cyclopentenol (9) compared to the cyclopentenol (7), the 1-position being that substituted by the free hydroxy-group in each case.

<sup>1</sup> A. Mitra, 'The Synthesis of Prostaglandins,' Wiley, New York, 1977; J. S. Bindra and R. Bindra, 'Prostaglandin Synthesis,' Academic Press, New York, 1977; 'Prostaglandin Research,' ed. P. Crabbé, Academic Press, New York, 1977.

<sup>2</sup> C. J. Sih, J. B. Heather, R. Sood, P. Price, G. Peruzzotti, L. F. H. Lee, and S. S. Lee, *J. Amer. Chem. Soc.*, 1975, **97**, 865.

<sup>3</sup> G. Stork and T. Takahashi, *J. Amer. Chem. Soc.*, 1977, **99**, 1275.

<sup>4</sup> J. G. Miller, W. Kurz, K. G. Untch, and G. Stork, *J. Amer. Chem. Soc.*, 1974, **96**, 6774.

<sup>5</sup> R. Pappo, P. Collins, and C. Jung, *Tetrahedron Letters*, 1973, 943.

<sup>6</sup> S. Kurozumi, T. Toru, and S. Ishimoto, *Tetrahedron Letters*, 1973, 4959.

<sup>7</sup> A. W. Burgstahler, T. B. Lewis, and M. O. Abdel-Rahman, *J. Org. Chem.*, 1966, **31**, 3516; C. J. Moye and S. Sternhell, *Austral. J. Chem.*, 1966, **19**, 2107.

<sup>8</sup> R. M. Christie, R. W. Rickards, K. J. Schmalzl, and D. Taylor, *Austral. J. Chem.*, 1977, **30**, 2195.

<sup>9</sup> R. Effenberger and R. W. Rickards, *Austral. J. Chem.*, 1975, **28**, 2731.

<sup>10</sup> M. Gill and R. W. Rickards, unpublished results.

<sup>11</sup> D. A. Evans, T. C. Crawford, T. T. Fujimoto, and R. C. Thomas, *J. Org. Chem.*, 1974, **39**, 3176.

<sup>12</sup> E. J. Corey and A. Venkateswarlu, *J. Amer. Chem. Soc.*, 1972, **94**, 6190.